VentriPoint Diagnostics (VPT) Q4 2024 earnings summary

Executive summary

• Ventripoint Diagnostics Ltd. develops and commercializes diagnostic tools for heart disease, focusing sales efforts primarily in Europe, with 75% of sales in that region over the last two years.

• The company reported a net loss of $4,919,573 for the year ended December 31, 2024, and negative cash flow from operations of $3,386,199.

• As of December 31, 2024, the company had an accumulated deficit of $58,412,522 and a shareholders' deficiency of $2,981,871.

• The auditor highlighted material uncertainty regarding the company's ability to continue as a going concern due to recurring losses and negative cash flows.

Financial highlights

• Revenue for 2024 was $95,172, up from $49,183 in 2023; gross margin was negative at $(6,749) in 2024.

• Total operating expenses were $4,896,988 in 2024, slightly down from $4,972,932 in 2023.

• Loss from operations was $(4,801,816) in 2024, compared to $(4,930,498) in 2023.

• Cash and cash equivalents decreased to $60,547 at year-end 2024 from $1,294,346 at year-end 2023.

• Net cash used in operating activities was $(3,386,199) in 2024, compared to $(3,803,894) in 2023.

Outlook and guidance

• The company plans to raise approximately $500,000 by the end of 2025 to support ongoing operations and product commercialization.